Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

20201,694 citationsJournal Articlebronze Open Access

Authors

Yi‐Long Wu · Guangdong Provincial People's Hospital

Masahiro Tsuboi · National Cancer Center Hospital East

Jie He · Chinese Academy of Medical Sciences & Peking Union Medical College

Thomas John · Austin Health

Christian Grohé · Evangelische Lungenklinik Berlin

Margarita Majem · Hospital de Sant Pau

Jonathan W. Goldman

Abstract

In patients with stage IB to IIIA <i>EGFR</i> mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 18, pp. 1711-1723

DOI: 10.1056/nejmoa2027071

Field-Weighted Citation Impact: 136.90